Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

IBA SA : TRANSPARENCY NOTIFICATION

IBA SA
Posted on: 10 Nov 16

IBA - TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, July 10, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on 7 July 2017*.

Reason for the notification Upwards crossing of the 3% threshold further to the acquisition of shares -and thus voting rights- held as loan collateral
Persons subject to the notification requirement IBA SA, issuer
Persons that dispose of voting rights Norges Bank
Transaction date  05/07/2017
Threshold that is crossed (in %)   3% (statutory threshold)
Upwards crossing further to the acquisition of voting rights
Denominator  29 852 549
Voting rights (number)  1 015 762
Voting rights (%)  3,40%
Chain of control N/A

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

* Erratum on "7 April 2017" previously communicated.

For further information, please contact:

IBA

Stephanie Bauwin
Legal Counsel
+32 10 203 924
Stephanie.bauwin@iba-group.com

20170710 transparency re Norge EN erratum


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: IBA SA via GlobeNewswire
HUG#2119737
GlobeNewswire
globenewswire.com

Last updated on: 12/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.